Differential protein stability and clinical responses ofEML4-ALK fusion variants to various ALK inhibitors in advancedALK-rearranged non-small cell lung cancer-Reference-Cited by-同舟云学术

Differential protein stability and clinical responses ofEML4-ALK fusion variants to various ALK inhibitors in advancedALK-rearranged non-small cell lung cancer

Published:2017-04 Issue:4 Volume:28 Page:791-797
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Woo C.G.,Seo S.,Kim S.W.,Jang S.J.,Park K.S.,Song J.Y.,Lee B.,Richards M.W.,Bayliss R.,Lee D.H.,Choi J.

Funder

Asan Institute for Life Sciences

Korea Health Technology R&D Project

Korea Health Industry Development Institute

Ministry of Health, Welfare and Family Affairs, Republic of Korea

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference26 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

3. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer;Rikova;Cell,2007

4. A mouse model for EML4-ALK-positive lung cancer;Soda;Proc Natl Acad Sci U S A,2008

5. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis;Shaw;Lancet Oncol,2011

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. EML4-ALK variant-specific genetic interactions shape lung tumorigenesis;2024-08-27

2. How to find a needle in a haystack: a systematic review on targeting KRAS wild-type pancreatic cancer;FUTURE ONCOL;2024

3. Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study;Journal of Clinical Oncology;2024-05-31

4. Concurrent inhibition of ALK and SRC kinases disrupts the ALK lung tumor cell proteome;Drug Resistance Updates;2024-05

5. The mesenchymal morphology of cells expressing the EML4–ALK V3 oncogene is dependent on phosphorylation of Eg5 by NEK7;Journal of Biological Chemistry;2024-05